Disease relevance of 3-DEAZAURIDINE

• 3-Deazauridine enhanced the anabolism of ara-C in nonleukemic lymphocytes in vitro and leukemia L1210 cells in vivo but did not influence ara-C anabolism in the other cell types [1].
• The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluorodeoxyuridine, and 3-deazauridine [2].
• Effects of 2-deoxy-D-glucose and 3 deazauridine individually and in combination on the replication of Japanese B encephalitis virus [3].
• Toxicity of combinations of arabinosylcytosine and 3-deazauridine toward neoplastic cells in culture [4].
• 3-Deazauridine triggers dose-dependent apoptosis in myeloid leukemia cells and enhances retinoic acid-induced granulocytic differentiation of HL-60 cells [5].

High impact information on 3-DEAZAURIDINE

• Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia [6].
• In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia [7].
• Pharmacokinetics and disposition of 3-deazauridine in humans [8].
• Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid [9].
• Under our experimental conditions, 3-deazauridine and hydroxyurea proved equally as effective as dThd in stimulating ddCyd phosphorylation [10].

Chemical compound and disease context of 3-DEAZAURIDINE

• Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model [11].

Biological context of 3-DEAZAURIDINE

• Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside [12].
• Therapeutic nucleoside analogue 3-deazauridine (DU) exerts cytotoxic activity against cancer cells by disruption of DNA synthesis resulting in cell death [5].
• Enhanced ara-CTP formation was observed in cells lacking cytidine deaminase (L1 210 and HL60), indicating that 3-deazauridine inhibition of deoxycytidylate deaminase may be important in this drug interaction [13].

Associations of 3-DEAZAURIDINE with other chemical compounds

• Most probably, these phenomena are related to the increased amounts of PRPP observed, which can result in an increased pyrimidine biosynthesis de novo and, as a consequence, a decreased metabolism of 3-deazauridine via the salvage pathway [14].
• The data indicate that 3-deazauridine may potentiate its own inhibition of CTP synthetase by reducing the concentration of competing uracil nucleotides by inhibiting de novo pyrimidine biosynthesis and pyrimidine salvage [15].
• Mycophenolic acid, an inhibitor of the enzyme IMP dehydrogenase, antagonizes the CTP synthetase inhibitor 3-deazauridine in its anti-proliferative effects on MOLT-3 human T leukemia cells [14].
• Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine [16].
• Enzyme pattern-directed chemotherapy: synergistic interaction of 3-deazauridine with D-galactosamine [17].

Gene context of 3-DEAZAURIDINE

• We also observed that p53 status influenced correlations between ENT1 transporter gene RNA levels and sensitivity to the drugs tiazafurin, AZQ and 3-deazauridine [18].
• Comparable results were obtained using 3-deazauridine, a known inhibitor of CTP synthetase [19].

Analytical, diagnostic and therapeutic context of 3-DEAZAURIDINE

• Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography [20].

References